Nivolumab/rHuPH20

BIOLOGICAL2 trials

Sponsors

Bristol-Myers Squibb

Conditions

MelanomaUrothelial Carcinoma

Phase 2

A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer

WithdrawnNCT05496192

Bristol-Myers SquibbMelanoma, Urothelial Carcinoma

Start: 2023-05-31End: 2026-06-24Updated: 2023-04-14

Phase 3

A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection

CompletedNCT05297565

Bristol-Myers SquibbMelanoma

Start: 2022-08-02End: 2024-02-08Updated: 2025-02-27